Perioperative Chemo and Pembrolizumab in Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 25, 2017

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Gastric CancerAdenocarcinoma of the Gastroesophageal Junction
Interventions
DRUG

Pembrolizumab

Pembrolizumab dosed IV at 200mg every 21 days per cycle.

DRUG

Standard of care chemotherapy regimen

"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."

Trial Locations (4)

10021

Weill Cornell Medical College/ NewYork-Presbyterian, New York

10032

Columbia University Medical Center, New York

63130

Haesong Park, St Louis

02912

Brown University, Providence

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Gulam Manji

OTHER

NCT02918162 - Perioperative Chemo and Pembrolizumab in Gastric Cancer | Biotech Hunter | Biotech Hunter